<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00161070</url>
  </required_header>
  <id_info>
    <org_study_id>96-217</org_study_id>
    <secondary_id>Heart Found.: 97.026</secondary_id>
    <secondary_id>Eur. Com.: QLK6-CT-2002-02332</secondary_id>
    <nct_id>NCT00161070</nct_id>
  </id_info>
  <brief_title>ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial</brief_title>
  <official_title>ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <brief_summary>
    <textblock>
      The objective of ESPRIT was to compare the efficacy and safety of mild anticoagulation or a
      combination treatment of aspirin and dipyridamole with the efficacy and safety of treatment
      with aspirin alone after cerebral ischemia of arterial origin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Low-dose aspirin (ASA) (at least 30 mg/day) prevents only 13% of subsequent vascular events
      after minor cerebral ischemia of arterial origin. Anticoagulation (AC) has been proven highly
      effective in preventing vascular events after myocardial infarction and after cerebral
      ischemia in patients with atrial fibrillation. A previous study on the effects of AC after
      cerebral ischemia of arterial origin (SPIRIT) showed that high intensity AC (INR 3.0 to 4.5)
      is not safe, but that mild AC (INR 2.0 to 3.0) was. The 2nd European Stroke Prevention Trial
      (ESPS-2) reported a 22% relative risk reduction of the combination of ASA and dipyridamole
      (DIP) above that of ASA only; its results, however, are subject to debate.

      Study design: ESPRIT was an open randomised controlled trial allocating patients who
      experienced a transient ischemic attack (TIA) or a non-disabling ischemic stroke to either:

      A. oral AC (INR 2.0 to 3.0);

      B. the combination of DIP (400 mg daily) plus ASA (30-325 mg/day); or

      C. ASA only (same dose).

      The mean follow-up was three years. Primary outcome was the composite of vascular death,
      stroke, myocardial infarction or major bleeding. Outcome assessment is blind.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1997</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The combined event of death from all vascular causes, nonfatal stroke, nonfatal myocardial infarction or major bleeding complication, whichever happens first during follow-up</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death from all causes</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death from vascular causes</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death from vascular causes or nonfatal stroke</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fatal or nonfatal stroke</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death from vascular causes, nonfatal stroke, nonfatal myocardial infarction or vascular intervention</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major bleeding complications</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amputations of lower extremities</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>retinal infarction or bleeding</measure>
  </secondary_outcome>
  <enrollment>4500</enrollment>
  <condition>Brain Ischemia</condition>
  <condition>Transient Ischemic Attack</condition>
  <condition>Arteriosclerosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anticoagulation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin and dipyridamole</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin alone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients presenting in the participating hospitals with a TIA or non-disabling stroke
             of atherosclerotic origin

          -  Randomisation within 6 months after the TIA or minor stroke

          -  Modified Rankin scale of 3 or less

        Exclusion Criteria:

          -  (Contra)indication to, or intolerance to, anticoagulants, dipyridamole, or aspirin

          -  Disease expected to cause death within weeks or months

          -  Source of embolism in the heart

          -  Moderate or severe ischemic damage to the white matter of the brain (leukoaraiosis)

          -  Anemia, polycythemia, thrombocytosis, or thrombocytopenia

          -  Planned carotid endarterectomy

          -  Intracranial bleeding or cerebral tumour

          -  TIA or stroke caused by vasculitis, migraine, or dissection

          -  Severe hypertension

          -  Liver failure

          -  Pregnancy

          -  Chronic alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Algra, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. Gijn Van, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006 May 20;367(9523):1665-73. Erratum in: Lancet. 2007 Jan 27;369(9558):274.</citation>
    <PMID>16714187</PMID>
  </results_reference>
  <results_reference>
    <citation>ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol. 2007 Feb;6(2):115-24.</citation>
    <PMID>17239798</PMID>
  </results_reference>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>March 21, 2007</last_update_submitted>
  <last_update_submitted_qc>March 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2007</last_update_posted>
  <keyword>secondary prevention</keyword>
  <keyword>TIA / minor stroke</keyword>
  <keyword>atherosclerotic origin</keyword>
  <keyword>TIA (Transient Ischemic Attack)</keyword>
  <keyword>prevention &amp; control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Dipyridamole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

